TY - JOUR T1 - Adaptive vaccination may be needed to eliminate COVID-19: Results from a runtime-alterable strain-drift and waning-immunity model JF - medRxiv DO - 10.1101/2021.06.07.21258504 SP - 2021.06.07.21258504 AU - Wayne M. Getz AU - Richard Salter AU - Ludovica Luisa Vissat AU - James S. Koopman AU - Carl P. Simon Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/16/2021.06.07.21258504.abstract N2 - We developed an elaborated susceptible-infected-recovered (SIR) individual-based model (IBM) with pathogen strain drift, waning and cross immunity, implemented as a novel Java Runtime-Alterable-Model Platform (J-RAMP). This platform allows parameter values, process formulations, and scriptable runtime drivers to be easily added at the start of simulation. It includes facility for integration into the R statistical and other data analysis platforms. We selected a set of parameter values and process descriptions relevant to the current COVID-19 pandemic. These include pathogen-specific shedding, environmental persistence, host transmission and mortality, within-host pathogen mutation and replication, adaptive social distancing, and time dependent vaccine rate and strain valency specifications. Our simulations illustrate that if waning immunity outpaces vaccination rates, then vaccination rollouts may fail to contain the most transmissible strains. Our study highlights the need for adaptive vaccination rollouts, which depend on reliable real-time monitoring and surveillance of strain proliferation and reinfection data needed to ensure that vaccines target emerging strains and constrain escape mutations. Together with such data, our platform has the potential to inform the design of vaccination programs that eliminate rather than exacerbate local outbreaks. Finally, our RAMP concept promotes the development of highly flexible models that can be easily shared among researchers and policymakers not only addressing healthcare crises, but other types of environmental crises as well.Significance Statement Effective COVID-19 vaccine development has been unprecedented, but vaccinations are being delivered at contrasting rates across the globe. Here, using an innovative epidemiological Java runtime alterable modeling platform (J-RAMP), we demonstrate that seemingly reasonable vaccination programs may exacerbate rather than mitigate regional outbreaks when immune waning outpaces vaccinations and reinfection promotes escape mutations. Our simulations suggest that adaptive vaccination programs, requiring adequate strain and serology monitoring and surveillance, are needed to eliminate outbreaks. Our platform provides policymakers with an easy-to-use tool for designing effective vaccination programs. Our RAMP concept points the way to the development of highly flexible models that are easily shared among researchers and policymakers in all areas of systems analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by NSF Grant 2032264 (PI: WMG)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable ER -